Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.5% |
| MARTINEZ, TARA L | 1 | 62.7% | +64.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17787228 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR | MARTINEZ, TARA L | 25d overdue |
| 17843796 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | JONES, DAMERON LEVEST | 39d |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17843796 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | JONES, DAMERON LEVEST | 1618 | §103 | Non-Final OA | 39d | Pending | Jun 17, 2022 |
| 17787228 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR | MARTINEZ, TARA L | 1654 | Other | Non-Final OA | 25d overdue | Pending | Jun 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial